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Objectives The goal of this study was to determine if biomarkers of subclinical myocardial injury and hemodynamic stress
identify asymptomatic individuals with left ventricular hypertrophy (LVH) at higher risk for heart failure (HF) and
death.
Background The interaction between LVH, low but detectable cardiac troponin T (cTnT), and elevated N-terminal pro–B-type
natriuretic peptide (NT-proBNP) on cardiovascular (CV) outcomes in the general population is unknown.
Methods Participants in the Dallas Heart Study without clinical HF, LV dysfunction, or chronic kidney disease underwent
measurement of LV mass by magnetic resonance imaging (MRI), cTnT by highly sensitive assay, and NT-proBNP
analysis (n  2,413). Subjects were stratified according to LVH and by detectable cTnT (3 pg/ml) and in-
creased NT-proBNP (75th age- and sex-specific percentile) levels. For each analysis, participants were catego-
rized into groups based on the presence () or absence (–) of LVH and biomarker levels above () or below (–)
the predefined threshold.
Results Nine percent of participants were LVH, 25% cTnT, and 24% NT-proBNP. Those LVH and cTnT and/or
NT-proBNP (n  144) were older and more likely to be male, with a greater risk factor burden and more se-
vere LVH compared with those who were LVH biomarker– (p  0.01 for each). The cumulative incidence of HF
or CV death over 8 years among LVH cTnT was 21% versus 1% (LVH– cTnT–), 4% (LVH– cTnT), and 6%
(LVH cTnT–) (p  0.0001). The interactions between LVH and cTnT (pinteraction  0.0005) and LVH and NT-
proBNP (pinteraction  0.014) were highly significant. Individuals who were LVH and either cTnT or NT-
proBNP remained at 4-fold higher risk for HF or CV death after multivariable adjustment for CV risk factors,
renal function, and LV mass compared with those who were LVH– biomarker–.
Conclusions Minimal elevations in biomarkers of subclinical cardiac injury and hemodynamic stress modify the association of
LVH with adverse outcomes, identifying a malignant subphenotype of LVH with high risk for progression to HF and
CV death. (J Am Coll Cardiol 2013;61:187–95) © 2013 by the American College of Cardiology Foundation
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LVH and Cardiac Biomarkers January 15, 2013:187–95Left ventricular (LV) hypertro-
phy (LVH), most commonly due
to chronic hypertensive heart
disease, is associated with sub-
stantial morbidity and mortality,
including the development of
heart failure (HF) and death
from cardiovascular (CV) disease
(1,2). LVH develops in response
to chronic pressure and volume
overload and may ultimately
progress to pathological systolic
or diastolic dysfunction and
symptomatic HF (3). Maladap-
tive LV remodeling plays a cen-
tral role in the transition from
asymptomatic LVH to clinical
HF and results from cardiomyo-
cyte injury and tissue fibrosis (4),
as well as increased diastolic wall
stress and neurohormonal activa-
tion (5).
Although clearly a risk factor
for HF and CV death, the natural history of LVH is
heterogeneous, with a progressive course in some individu-
als but an uncomplicated course in many others. Identifi-
cation of biological pathways that contribute to the transi-
tion from LVH to clinical HF, and biomarkers that
accurately represent these pathways, may help to identify
individuals at high risk for adverse outcomes and to
develop therapeutic targets to prevent disease transition.
Biomarkers of myocardial injury and neurohormonal
activation due to hemodynamic stress may therefore play
key roles in defining the transition from asymptomatic LVH
to clinical HF (6–8).
Cardiac troponin T (cTnT) and N-terminal pro–B-type
natriuretic peptide (NT-proBNP) are released from cardiac
myocytes in response to a variety of pathological stimuli,
including increased LV wall stress and hypertrophy, and are
markers of cardiac injury and ventricular wall stress (9,10).
oth biomarkers have been shown to associate strongly with
ncident HF (11,12) and mortality (13,14) in the general
opulation; however, the impact of minimally elevated
irculating levels of cTnT and NT-proBNP among indi-
iduals with LVH is unknown. Our goal was to test the
ypothesis that biomarker evidence of subclinical myocar-
ial injury and hemodynamic stress could identify asymp-
omatic individuals with LVH at higher risk for transition
o HF and CV death.
ethods
tudy population. The Dallas Heart Study (DHS) is a
ultiethnic, probability-based, population cohort study of
allas County adults in which deliberate oversampling of
Abbreviations
and Acronyms
BSA  body surface area
CI  confidence interval
cTnT  cardiac troponin T
CV  cardiovascular
ECG  electrocardiogram
eGFR  estimated
glomerular filtration rate
HF  heart failure
HR  hazard ratio
LV  left ventricular
LVEF  left ventricular
ejection fraction
LVH  left ventricular
hypertrophy
MRI  magnetic resonance
imaging
NT-proBNP  N-terminal
pro–B-type natriuretic
peptidefrican-Americans was performed. Detailed methods of the aHS have been described previously (15). Briefly, between
000 and 2002, a total of 3,072 subjects completed the 3
HS visits, including a detailed in-home survey, laboratory
esting, and imaging studies. Participants were then fol-
owed up for the occurrence of predefined clinical events and
eath. For the current study, we excluded participants with
n LV ejection fraction (LVEF) 40%, estimated glomer-
lar filtration rate (eGFR) 60 ml/min/1.73 m2, and those
with prevalent clinical HF (defined by self-report of “con-
gestive heart failure, an enlarged heart, a weak heart, or
cardiomyopathy”) at baseline, yielding a final sample size of
2,413. Participants provided written informed consent, and
the protocol was approved by the institutional review board
of University of Texas Southwestern Medical Center.
Biomarker, imaging, and body composition measure-
ments. Detailed methods describing measurements of
cTnT by using a highly sensitive assay (Elecsys-2010
Troponin T hs STAT, Roche Diagnostics, Indianapolis,
Indiana) and NT-proBNP (Elecsys, Roche Diagnostics) in
the DHS have been published previously (14,16). The
lowest concentrations within the analytical measurement
range of the assays were 3 pg/ml and 5 pg/ml for cTnT and
NT-proBNP, respectively. Cardiac magnetic resonance im-
aging (MRI) was performed by using a 1.5-T system
(Intera, Philips Medical Systems, Best, the Netherlands).
LV mass, wall thickness, end-diastolic and end-systolic
volumes, and LVEF were calculated from short-axis se-
quences. LV concentricity was defined as the ratio of LV
mass to end-diastolic volume (17).
Fat-free mass was measured with dual-energy x-ray
absorptiometry (Delphi W scanner, Hologic, Inc., Bedford,
Massachusetts, and Discovery software [version 12.2]) (18).
Body mass index was calculated as weight (kilograms)/
height (meters)2 based on weight and height measured at
study entry. Body surface area (BSA) was calculated by
using the method of Tikuisis et al. (19). Twelve-lead
electrocardiograms (ECG) were recorded at 25 mm/s and 1
mV/cm standardization, with a sampling rate of 0.5 kHz, by
using the Marquette 12SL ECG analysis program version
229 (GE Marquette Medical Systems, Milwaukee, Wiscon-
sin). Voltage measurements were obtained electronically by
using median voltages from an aligned group of all beats
from each lead. Two DHS investigators blinded to demo-
graphic and clinical information reviewed each ECG to
verify the computer-identified parameters and to provide a
clinical interpretation.
Definitions. LVH was defined as LV mass/BSA 89
g/m2 in women and 112 g/m2 in men, based on a
phenotypically normal subpopulation of the DHS cohort, as
previously described (17). As a sensitivity analysis, LVH was
also defined by indexing LV mass to height2.7 (LV mass/
eight2.7 39 g/m2.7 [women] and 48 g/m2.7 [men]) and
at-free mass (LV mass/fat-free mass 3.7 g/kg [both men
nd women]). Analyses of LVH according to the Sokolow-
yon ECG criteria, defined as the sum of the S-wave
mplitude in lead V1 plus the maximum R-wave amplitude
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January 15, 2013:187–95 LVH and Cardiac Biomarkersin V5 or V6 3.5 mV (35 mm) or aVL R-wave amplitude
1.1 mV (11 mm) (20), were also performed.
cTnT was characterized as elevated if equal to or above
the limit of blank of the assay (3 pg/ml). The limit of blank
corresponds to the lowest cTnT concentration within the
analytical measurement range of the assay. NT-proBNP
was defined as increased if above the age- and sex-specific
75th percentile of the population (using 5 age categories
with cutoffs of 35, 40, 50, and 60 years). The NT-proBNP
threshold at the 75th percentile was selected to yield a
similar proportion of individuals characterized with elevated
NT-proBNP as with detectable cTnT. Both thresholds
were prospectively defined based on prior studies (14,21).
Race/ethnicity, history of CV diseases, and smoking
status were self-reported. Detailed descriptions of variable
definitions for hypertension, hypercholesterolemia, and low
high-density lipoprotein cholesterol have been previously
described by using conventional clinical definitions (22).
Presence of the metabolic syndrome was defined and
Framingham 10-year CVD risk estimates were calculated
according to the National Cholesterol Education Pro-
gram’s Adult Treatment Panel III report (23). GFR was
estimated by using the Modification of Diet in Renal
Disease equation (24).
Outcomes. The primary outcome was the composite of
incident HF or CV death. Incident HF was defined as first
hospitalization for systolic or diastolic HF as determined
through: 1) a detailed health survey regarding interval CV
events administered by the Data Coordinating Center
during annual calls to study subjects; and/or 2) for subjects
providing informed consent (90%), quarterly tracking for
hospital admissions using the Dallas–Fort Worth Hospital
Council Data Initiative database, which includes all hospital
admission data for 70 of 72 hospitals in the Dallas–Fort
Worth area. Primary clinical source documents were col-
lected and reviewed for all suspected nonfatal CV events
(including myocardial infarction and HF) and were inde-
pendently adjudicated by a blinded endpoint committee.
Systolic HF was defined as a clinical diagnosis of symptom-
atic HF in the setting of an LVEF50% or documentation
of a “depressed or low” LVEF. Diastolic HF was defined as
a clinical diagnosis of symptomatic HF in the setting of an
LVEF 50% or documentation of a “preserved or normal”
LVEF. Death events were ascertained through December
31, 2009, from the National Death Index and classified as
CV if the primary cause was related to the cardiovascular
system according to the International Statistical Classifica-
tion of Diseases, 10th Revision codes I00–I99 (25).
Statistical analysis. For each analysis, participants were
categorized into groups based on the presence () or
absence (–) of LVH and biomarker levels above () or
below (–) the predefined threshold. Baseline characteristics
were compared between those without LVH, those with
LVH but without elevated biomarkers, and those with
LVH and elevated biomarkers by using chi-square tests for
dichotomous variables and Wilcoxon rank sum tests for wcontinuous variables. The cumulative incidence of the pri-
mary outcome among groups with LVH biomarker–,
LVH biomarker, LVH biomarker, and LVH
biomarker was estimated by using time-to-event analysis,
and Kaplan-Meier curves were constructed and compared
by using the log-rank test. Cox proportional hazards models
were used to calculate the hazard ratios (HRs) and 95%
confidence intervals (CIs) for the primary outcome among
each group after conditions of proportionality were con-
firmed. Interaction terms were included in the unadjusted
models to determine if qualitative interactions between
LVH, cTnT, and NT-proBNP were present. Multivariable
models were used to adjust for age, sex, African-American
race, diabetes, hypertension, prior CV disease, smoking,
body mass index, eGFR, and LV mass/BSA. Shrinkage
coefficients were tested for each multivariable model to
ensure against model overfitting. Sensitivity analyses were
performed by using a 5-pg/ml threshold to define detectable
cTnT and defining LVH by using LV mass indexed to
height2.7 and fat-free mass, and also according to the
okolow-Lyon ECG criteria. Exploratory analyses were
erformed by comparing outcomes among those with LVH
nd 0, 1, or 2 elevated biomarkers.
For all statistical testing, a 2-sided p value 0.05 was
onsidered statistically significant. All statistical analyses
ere performed by using SAS version 9.2 (SAS Institute,
nc., Cary, North Carolina).
esults
revalence and univariable associations of LVH pheno-
ypes. Among the 2,413 participants meeting study criteria
mean age 44; 56% women; 48% African-American), 223
9.2%) had LVH, 590 (24.5%) had detectable cTnT
cTnT), and 584 (24.2%) had a NT-proBNP value75th
ercentile (NT-proBNP). The correlation between cTnT
nd NT-proBNP among all study participants was not
ignificant (Spearman’s rho  0.03, p  0.14); however,
mong the subgroup with detectable cTnT, NT-proBNP
as weakly correlated with cTnT (Spearman’s rho  0.14,
 0.001). Among those with LVH, 35.4% had no
iomarker elevation, 20.2% were cTnT only, 18.8 % were
T-proBNP only, and 25.6% were both cTnT and
T-proBNP. The frequency of LVH with cTnT was
ighest in African-American men (12%), with sequentially
ower rates seen in African-American women (4%), Cauca-
ian men (2%), and Caucasian women (1%), respectively.
Baseline characteristics are presented in Table 1. Com-
ared with both those without LVH and those with LVH
ut without detectable cTnT, participants with LVH and
etectable cTnT were older, more likely to be male and
frican American, with more hypertension, diabetes, met-
bolic syndrome, prior CVD, and lower eGFR (p  0.05
or each). In addition, compared with LVH cTnT–
ndividuals, those LVH cTnT had greater LV mass and
all thickness, a higher LV concentricity index, and higher
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LVH and Cardiac Biomarkers January 15, 2013:187–95levels of NT-proBNP. Generally similar findings were seen
when LVH NT-proBNP individuals were compared
ith LVH NT-proBNP– individuals, with the exception
hat larger LV end-diastolic and end-systolic volumes,
ather than wall thickness and concentricity, were associated
ith increased NT-proBNP.
ssociations of LVH phenotypes with HF and CV
eath. During a median follow-up period of 8.1 (interquar-
ile range 7.6 to 8.6) years, the primary outcome of HF or
V death occurred in 65 (2.7%) participants, including 28
F events (1.36 per 1,000 person-years) and 37 CV deaths
1.80 per 1,000 person-years). Among those who developed
F or died of CV causes, 63.1% were men and 78.5% were
frican-American. Of those with incident HF, 65.2% had
ystolic HF and 34.8% had diastolic HF, with a median
VEF at the time of diagnosis of 30% (interquartile range
0 to 36) and 55% (interquartile range 55 to 70), respec-
ively; 20% of those with systolic HF and 25% with diastolic
F had a myocardial infarction during the study interval.
The cumulative incidence of HF or CV death was 20.6%
Baseline Characteristics of the Study PopulationTable 1 Baseline Characteristics of the Study Population
Variable
No LVH
(n  2,190)
cTnT–
(n  121)
Age (yrs) 43 (36, 51) 43 (37, 50)
Male (%) 43.7 31.4
Race (%)
Caucasian 35.8 16.5
African-American 45.0 76.9
Hispanic 17.0 5.0
Other 2.1 1.7
Hypertension (%) 27.3 65.8
Systolic BP (mm Hg) 120 (111, 130) 138 (123, 15
Diastolic BP (mm Hg) 76 (71, 83) 84 (78, 95)
Diabetes (%) 8.5 14.0
Hypercholesterolemia (%) 13.1 11.6
Low HDL cholesterol (%) 39.4 38.0
Metabolic syndrome (%) 31.8 42.1
Current smoking (%) 24.7 49.6
Prior CHD (%) 1.6 1.7
Prior CVD (%) 2.9 5.0
Framingham 10-year CVD risk estimate
6 (%)
16.6 24.0
Estimated GFR (ml/min per 1.73 m2) 97.1 (85.3, 111.4) 103.9 (91.1, 11
Body mass index (kg/m2) 29.1 (25.2, 33.9) 29.0 (25.5, 34
LV mass/BSA (g/m2) 77.5 (68.7, 88.0) 103.7 (93.1, 11
LV wall thickness (mm) 11.2 (10.2, 12.3) 13.5 (12.3, 14
LV ejection fraction (%) 73.3 (68.4, 77.7) 71.7 (65.6, 75
LV end-diastolic volume/BSA (ml/m2) 50.6 (44.7, 57.0) 55.6 (49.0, 62
LV end-systolic volume/BSA (ml/m2) 13.4 (10.6, 16.7) 16.1 (12.5, 20
Concentricity (g/ml) 1.5 (1.4, 1.7) 1.9 (1.7, 2.1
cTnT (pg/ml) 3.0 (3.0,3.0) 3.0 (3.0,
NT-proBNP (pg/ml) 26.4 (12.6, 52.9) 35.5 (13.1, 85
Values are median (25%, 75% percentile) or proportion (%) where indicated. *p  0.05 versus no
()  presence; (–)  absence; BP  blood pressure; BSA  body surface area; CHD  coron
ate; HDL  high density lipoprotein; LV  left ventricular; LVH  left ventricular hypertrophy; NT-n the LVH cTnT group compared with 1.1% (LVH– ccTnT–), 3.9% (LVH– cTnT), and 5.8% (LVH cTnT–)
(log-rank p  0.0001) (Fig. 1A). Among those who were
LVH NT-proBNP, the primary outcome occurred in
20.2% compared with 1.5% (LVH– NT-proBNP–), 2.5%
(LVH– NT-proBNP), and 6.5% (LVH NT-proBNP–)
(log-rank p  0.0001) (Fig. 1B). Although only 6% of the
study population had LVH with cTnT and/or NT-
proBNP, these individuals accounted for approximately
40% of all HF or CV death events. The crude HR with 95%
CI for the primary outcome was 22.6 (95% CI 12.1 to 42.5)
for LVH cTnT and 15.5 (95% CI 8.6 to 28.0) for
LVH NT-proBNP participants compared with those
who were LVH– cTnT– and LVH– NT-proBNP–, respec-
tively (Table 2). Highly significant statistical interactions
were observed both between LVH and detectable cTnT
(pinteraction0.0005) and between LVH and elevated NT-
proBNP (pinteraction  0.014) for the primary outcome. Inter-
ctions remained significant after including each biomarker as
continuous variable (pinteraction  0.026 for LVH-cTnT and
interaction  0.044 for LVH-NT-proBNP). Findings were
LVH LVH
cTnT
(n  102)
NT-proBNP–
(n  124)
NT-proBNP
(n  99)
51 (45, 59)*† 45 (38, 53) 49 (42, 56)*‡
68.6*† 45.2 52.5
14.7* 14.5 17.2*
78.4* 78.2 76.8*
6.9* 5.6 6.1*
0.0 0.0 0.0
76.8* 64.2 79.2*
151 (134, 167)*† 139 (123, 153) 154 (132, 170)*‡
87 (79, 94)* 83 (77, 93) 89 (80, 100)*‡
30.4*† 20.2 23.2*
15.7 13.7 13.1
38.2 38.7 37.4
58.8*† 50.8 48.5*
29.4† 36.3 45.5*
10.8*† 3.2 9.1*
15.7*† 4.0 17.2*‡
52.9*† 31.5 44.4*
93.5 (80.3, 108.6)*† 98.3 (86.4, 115.1) 97.6 (83.9, 112.2)
31.0 (26.3, 35.7)* 29.7 (26.4, 34.9) 29.5 (25.2, 35.4)
119.4 (108.2, 129.0)*† 108.7 (94.6, 117.7) 119.8 (101.1, 130.0)*‡
14.6 (13.7, 16.4)*† 13.9 (13.0, 15.1) 14.3 (12.9, 15.4)*
70.5 (61.9, 76.0)* 71.8 (66.3, 75.6) 70.5 (62.8, 76.3)*
58.1 (48.6, 68.1)* 54.9 (47.6, 62.1) 58.4 (50.1, 68.7)*‡
16.1 (12.9, 22.9)* 15.1 (12.3, 20.2) 17.3 (13.1, 23.0)*‡
2.0 (1.8, 2.5)*† 1.9 (1.7, 2.3) 1.9 (1.7, 2.3)*
7.4 (5.1, 10.9)*† 3.0 (3.0, 4.8) 4.1 (3.0, 9.7)*‡
71.0 (25.9, 194.0)*† 20.1 (9.4, 39.4) 127 (86.2, 257.7)*‡
oup. †p  0.05 versus LVH cTnT– group. ‡p  0.05 versus LVH NT-proBNP– group.
rt disease; cTnT  cardiac troponin T; CVD  cardiovascular disease; GFR  glomerular filtration
 N-terminal pro–B-type natriuretic peptide.6)
6.3)
.7)
6.9)
.5)
.9)
.8)
.2)
)
3.0)
.5)
LVH gronsistent across subgroups defined by age, sex, race, ejec-
if
o
s
H
w
L
e

f
p
i
[
c
p
N
e
a
b
p
n
c
a
0
A
i
w
a
v
r
L
f
s
191JACC Vol. 61, No. 2, 2013 Neeland et al.
January 15, 2013:187–95 LVH and Cardiac Biomarkerstion fraction, and comorbidities (Online Fig. 1) and for both
ndividual components of the composite outcome (Fig. 2).
Results were also insensitive to the use of height2.7 or
at-free mass as the indexing variable for LV mass and to use
Figure 1 Kaplan-Meier Curves for Incident HF or CV Death
Unadjusted Kaplan-Meier curves for incident heart failure (HF) or cardiovascular
(CV) death stratified by the presence () or absence (–) of left ventricular
hypertrophy (LVH) and detectable cardiac troponin T (A) or increased N-terminal
pro–B-type natriuretic peptide (NT-proBNP) (B). cTnT  cardiac troponin T.
Unadjusted and Multivariable-Adjusted Associations of LVHTable 2 Unadjusted and Multivariable-Adjusted Associations of
Model LVH– cTnT–* LVH– cTnT
Model 1 (unadjusted) 1.00 3.7 (2.0, 7.1)
Model 2 1.00 1.8 (0.9, 3.9)
Model 3 1.00 1.9 (0.9, 4.0)
LVH–
NT-proBNP–*
LVH– NT-
proBNP
Model 1 (unadjusted) 1.00 1.7 (0.8, 3.3
Model 2 1.00 2.2 (1.0, 4.5
Model 3 1.00 2.1 (1.0, 4.4
Model 1 was unadjusted; Model 2 was adjusted for age, sex, African-American race, diabetes, hyp
plus LV mass/BSA. *Referent.
Abbreviations as in Table 1.f a 5-pg/ml threshold to define detectable cTnT (data not
hown).
Detectable cTnT was associated with a higher risk for
F or CV death across sex-specific tertiles of LV mass,
ith the largest effect seen among those with the highest
V mass (p  0.0001 for cTnT vs. cTnT– in tertile 3,
Fig. 3A), consistent with the statistical interaction reported
earlier. In addition, the presence of LVH was associated
with a marked increase in the risk for HF or CV death
across the entire spectrum of cTnT levels (p  0.001 for
ach) (Fig. 3B), with the greatest effect seen at cTnT levels
14 pg/ml (the previously reported 99th percentile value
or the assay in normal controls).
Among the subgroup of individuals with LVH, the
resence of detectable cTnT was associated with a 4-fold
ncrease in the risk of the composite outcome (crude HR 4.2
95% CI 1.8 to 9.8]) compared with those who were LVH
TnT–. Similar findings were seen for the LVH NT-
roBNP group compared with those who were LVH
T-proBNP– (crude HR 3.5 [95% CI 1.5 to 7.9]). In
xploratory analyses restricted to those with LVH, graded
ssociations were also seen between the number of elevated
iomarkers and the incidence of HF or CV death. The
rimary outcome occurred in 5.1% of those with LVH and
ormal biomarkers, 8.1% of those with LVH and either
TnT or NT-proBNP, and 29.8% of those with LVH
nd both cTnT and NT-proBNP (log-rank p 
.0001) (Fig. 4).
In multivariable analyses adjusting for age, sex, African-
merican race, diabetes, hypertension, CV disease, smok-
ng, body mass index, eGFR, and LV mass/BSA, LVH
ith cTnT or NT-proBNP remained strongly associ-
ted with incident HF or CV death compared with indi-
iduals who were LVH– and cTnT– or NT-proBNP–,
espectively (adjusted HR 4.3 [95% CI 1.7 to 11.1] for
VH cTnT and adjusted HR 4.5 [95% CI 1.7 to 11.8]
or LVH NT-proBNP) (Table 2). Results were insen-
itive to substitution of systolic blood pressure (as a contin-
Hazard Ratio (95% CI)
p Value
for interactionLVH cTnT– LVH cTnT
5.5 (2.8, 13.1) 22.6 (12.1, 42.5) 0.0005
2.8 (1.1, 7.0) 6.2 (2.8, 13.7)
2.0 (0.7, 5.7) 4.3 (1.7, 11.1)
LVH NT–
proBNP–
LVH NT-
proBNP
4.5 (2.0, 9.9) 15.5 (8.6, 28.0) 0.014
2.4 (1.1, 5.6) 6.0 (3.0, 11.8)
2.0 (0.8, 5.3) 4.5 (1.7, 11.8)
on, prior CVD, smoking, body mass index, and estimated GFR; Model 3 was adjusted for Model 2LVH
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model.
Replacing MRI definitions of LVH with electrocardio-
graphic LVH criteria. Using the Sokolow-Lyon ECG
criteria, 215 (8.9%) participants had LVH, of whom 35.8%
were cTnT and 32.9% NT-proBNP. The primary
utcome occurred in 16.9% who were ECG LVH
TnT compared with 1.3% (ECG LVH– cTnT–), 5.3%
ECG LVH– cTnT), and 2.9% (ECG LVH cTnT–)
log-rank p  0.0001) (Online Fig. 2A). Among those who
ere ECG LVH NT-proBNP, the primary outcome
ccurred in 15.7% compared with 1.6% (ECG LVH–
T-proBNP–), 4.1% (ECG LVH– NT-proBNP), and
.2% (ECG LVH NT-proBNP–) (log-rank p  0.0001)
(Online Fig. 2B). Significant interactions were observed
between ECG LVH and both cTnT (pinteraction 0.013) and
T-proBNP (pinteraction  0.017) for the primary outcome.
ssociations remained significant after multivariable adjust-
ent, with an adjusted HR of 3.2 (95% CI 1.4 to 7.6) for
CG LVH cTnT and an adjusted HR 3.4 (95% CI 1.5 to
.9) for ECG LVH NT-proBNP compared with ECG
VH– biomarker–groups (Online Table 1).
iscussion
n a representative population-based sample of US adults
ithout HF, we report substantial heterogeneity in the
linical phenotype of LVH, with a very high risk of HF or
Figure 2 Incidence of HF and CV Death Stratified According to
Incidence of HF and CV death stratified according to the presence () or absence
increased NT-proBNP (C and D) levels. Abbreviations as given in Figure 1.V death observed among individuals who have LVH with aoncomitant biomarker evidence of subclinical myocardial
njury or neurohormonal activation due to hemodynamic
tress, and a more benign course among those with LVH
ut without elevated biomarkers. Although high-risk phe-
otypes with LVH and biomarker elevation were observed
n fewer than 6% of the population at baseline, such
ndividuals represented approximately 40% of HF or CV
eath events during follow-up. Moreover, these associations
ere independent of traditional CV risk factors and renal
unction, and were consistent across subgroups defined
ccording to age, sex, race, and baseline LVEF. The
ndings were insensitive to indexing methods for LVH and
erformed similarly when LVH was defined by using ECG
riteria, suggesting that simple and inexpensive strategies
ay be available to identify this high-risk group. Impor-
antly, the observations are not explained simply by higher
V mass among those with abnormal cTnT or NT-
roBNP because the findings were also robust to further
djustment for precise MRI measurements of LV mass.
ased on these findings, small elevations in cTnT and
T-proBNP may be pathophysiological indicators of ad-
erse remodeling on the pathway from LVH to clinical HF
nd not merely surrogate markers for more severe LVH.
Increasing evidence suggests that circulating biomarkers
f cardiac injury and neurohormonal activation provide
iological insight into chronic CV disease in the population.
tudies have demonstrated that cTnT is detectable by using
arker Group
LVH and detectable cTnT (A and B) orBiom
(–) ofhighly sensitive assay in 90% of patients with chronic
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and in 25% to 67% of middle-aged adults in the general
population (12,14). The concentration of NT-proBNP also
varies widely in the population, with the highest levels
among those of older age and female sex (28). LVH has
been shown to be an independent determinant of circulating
cTnT and NT-proBNP levels in stable, ambulatory popu-
lations (29–31). In our study, the prevalence of cTnT and
NT-proBNP was twice as high among those with LVH
compared with those without, and higher levels of both
markers were associated with more severe LVH. Notably,
within the population with LVH, structural changes asso-
ciated with cTnT included increased LV wall thickness and
concentricity; in contrast, NT-proBNP associated with
increased LV end-diastolic and end-systolic volumes. These
findings, along with the observation that cTnT and NT-
proBNP were weakly correlated with each other in our
study, support the notion that each biomarker may reflect
partially overlapping but nonredundant pathways through
which LVH can transition to clinical HF.
LVH is independently associated with adverse CV out-
comes, including HF and death. Each 50-g increment in
Figure 3 Incidence of HF or CV Death
(A) Incidence of HF or CV death by tertile of left ventricular (LV) mass stratified
according to detectable or undetectable cTnT. (B) Incidence of HF or CV death
according to cTnT level stratified by the presence or absence of LVH. BSA 
body surface area; other abbreviations as in Figure 1.echocardiographically assessed LV mass was associated witha 73% increased risk of CV death among men and a 112%
increased risk among women in the Framingham Heart
Study (2) and a 50% increased risk of developing systolic
HF in the Cardiovascular Health Study (1). Although
interval myocardial infarction is an important contributor to
the transition from LVH with a normal LVEF to a reduced
LVEF, our findings raise the possibility that chronic sub-
clinical myocardial injury may mediate the progression from
concentric LVH to LV systolic dysfunction in some indi-
viduals without myocardial infarction. In addition, given
that much of the progression to HF occurred among those
with preserved LVEF, our findings also suggest that cardiac
injury and hemodynamic stress may be important in the
transition from LVH to diastolic HF.
The interaction between LVH and cTnT and NT-
proBNP has not been previously described. Investigators
from the PEACE (Prevention of Events with Angiotensin-
Converting Enzyme Inhibition) trial demonstrated that
each unit increase in cTnT (measured by using a highly
sensitive assay) was associated with a 2-fold risk of HF
among patients with stable coronary artery disease and
normal LVEF, independent of NT-proBNP levels (26).
imilar associations have been observed in ambulatory
ohorts representative of the general population, where very
ow concentrations of cTnT (measured by using a highly
ensitive assay) and NT-proBNP confer independent prog-
ostic information with regard to HF, as well as CV and
ll-cause mortality (12,14,32). However, data on patient
ubgroups with LVH are lacking. Our study provides robust
vidence for effect modification of the association between
VH and HF and CV death by both cTnT and NT-
roBNP, as highly significant interaction terms were seen.
n addition, although only exploratory, we found an abso-
ute 25% increase in the risk for HF or CV death among
hose with LVH and elevation in both biomarkers com-
Figure 4 Unadjusted Kaplan-Meier Curves
for Incident HF or CV Death
Data from individuals with LVH stratified according to
number of elevated biomarkers. Abbreviations as in Figure 1.
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LVH and Cardiac Biomarkers January 15, 2013:187–95pared with those with LVH alone. These findings suggest
that not only do cardiac injury and neurohormonal activa-
tion independently confer an adverse prognosis among
individuals with LVH, but they likely reflect ongoing
processes that act synergistically to contribute to the tran-
sition from asymptomatic LVH to clinical HF. Future
studies evaluating associations of these biomarkers with
imaging-based assessments of cardiac remodeling in indi-
viduals with LVH are needed.
Clinical and therapeutic implications. African-American
individuals have an increased prevalence of LVH and are at
increased risk for HF and CV death compared with other
racial/ethnic groups (17). Although the associations of
cTnT, NT-proBNP, and LVH on HF and CV death were
consistent across race/ethnicity subgroups in this study
(Online Fig. 1), it is important to note that African-
American men had the highest proportion of LVH and
detectable cTnT within the study cohort and that the
majority of the events occurred among this subgroup. A
particularly notable finding is that African-American
women were more likely than Caucasian men to have the
LVH cTnT phenotype. Given that African-Americans
are 8 times as likely to have hypertension as an antecedent
to clinical HF (33) and 2 to 3 times more likely to have
LVH (17) compared with Caucasians, our findings may
contribute to understanding the biological mechanisms
underpinning the disproportionate burden of HF and CV
death among African-Americans.
Preliminary observations suggest that levels of both cTnT
(34) and NT-proBNP (35), as well as the subsequent risk
for death and HF associated with elevations in these
biomarkers, may be modifiable. Given the extraordinarily
high risk observed in the subgroups with LVH and abnor-
mal biomarkers, early identification and targeted treatments
to modify this malignant phenotype represent an important
clinical and research priority, with particular implications
for African-American individuals.
Currently, screening for LVH in the population is per-
formed most extensively with ECG, although the preva-
lence of ECG LVH varies significantly according to age,
sex, race, and ECG criteria used. ECG criteria systemati-
cally underestimate the true prevalence of LVH by MRI,
with ECG LVH prevalence ranging between 0.6% (2) and
4.9% (36) compared with an MRI prevalence of 7.7% (37)
in the Multi-Ethnic Study of Atherosclerosis and 9.2% in
the current study. Despite systematic misclassification by
ECG of a significant proportion of participants as not
having LVH, the finding of an interaction between LVH
and cTnT and NT-proBNP was maintained, such that
those with ECG-defined LVH and elevated cardiac bio-
markers had an absolute increased risk for HF or CV death
of 11% compared with those with ECG-defined LVH
but without elevated biomarkers. These findings suggest
that biomarkers may be used to subphenotype those with
ECG-defined LVH, identifying individuals at particularly
high risk for transition to cardiac failure and death. Theclinical implications of this approach require further pro-
spective study.
Study strengths and limitations. Strengths of the current
study include use of both advanced cardiac MRI imaging
and standard ECG criteria to define LVH, the assessment
of cardiac injury by using a novel, highly sensitive troponin
assay, and longitudinal follow-up in a well-validated pro-
spective cohort. In addition, the large proportion of
African-American patients included in our study population
allows robust examination of outcomes in this important
subgroup. Several limitations also merit comment. First, the
number of HF and CV death events was relatively small
despite the large sample size, due to the low-risk general
population sample studied. For this reason, our findings are
preliminary and should be primarily considered in light of
their pathophysiological, rather than clinical, implications.
Further study is required to validate these observations in
larger populations with LVH and long-term follow-up.
Second, extrapolation to older populations from our rela-
tively young cohort should not be made because older
populations have higher cTnT (32) and NT-proBNP levels,
and different thresholds may be needed to explore potential
interactions with LVH. Third, the prognostic differences
between LVH with elevation in a single biomarker com-
pared with both biomarkers should be considered
hypothesis-generating given the relatively low number of
participants and events modeled in these groups.
Conclusions
Elevated circulating levels of cTnT and NT-proBNP iden-
tified a malignant LVH phenotype in the general popula-
tion, reflecting chronic cardiac injury and hemodynamic
stress that may contribute to the transition from asymptom-
atic LVH to clinical HF. Highly significant interactions
were observed between LVH and both cTnT and NT-
proBNP, as individuals with LVH and elevated biomarkers
had an extremely high risk for HF or CV death over 8 years
of follow-up. These findings suggest that circulating cTnT
and NT-proBNP may identify a subpopulation of those
with LVH in need of aggressive prevention and treatment
to improve CV outcomes.
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